Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OvaZoa Reserve is a multi-ingredient oral nutraceutical supplement developed and marketed by MMC Healthcare (also known as MMC Pharmaceuticals) specifically for female reproductive health and the management of infertility. Launched in October 2023 under the company's Ziva division, the formulation is designed to support ovarian reserve and oocyte quality. It contains a combination of the androgen precursor dehydroepiandrosterone (DHEA), antioxidants such as ubiquinol (Coenzyme Q10), melatonin, and vitamin E, alongside essential nutrients including levomefolate (L-methylfolate), vitamin D3, zinc sulfate, and leucine. The product functions by providing hormonal support and reducing oxidative stress within the follicular environment to improve reproductive outcomes in women undergoing infertility management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OvaZoa Reserve.